

# Completion of substantial q16 molecular diagnostics order

## Completion of substantial q16 molecular diagnostics order expands clinical diagnostic reach in fast growing Chinese market

**Paris, France and Camberley, UK – 6th December 2018** – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, today announces it has received another substantial order for Primerdesign's **q16 molecular instruments** from a new customer within the fast growing Chinese market. The order for 100 molecular diagnostic instruments has been paid in advance and takes the number of q16 instruments sold into the Asia Pacific region to over 230 units.